Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Bio/pharma IPRs by the numbers

Figures discussed at the BIO International Convention reveal that bio/pharma IPRs at the Patent Trial and Appeal Board have a lower institution rate and lower claim-cancellation rate than for all IPRs

According to the USPTO’s latest statistics, there have been 108 PTAB petitions filed in the TC 1600 class covering bio/pharma patents. This is 8.1% of all petitions filed.

At the BIO International Convention, the USPTO’s Jackie Wright Bonilla provided further detail on how the TC 1600 class stacks up to others.

She revealed the TC 1600 class has a 64% institution rate for inter partes review (IPR) petitions. This is lower than the 76% institution rate for all IPRs.

The rate of claims being cancelled by the Board in pharma IPRs is also below the average. The TC 1600 class has had 28 final written decisions. In these, 75.5% of instituted claims were cancelled (309 claims cancelled and 100 claims found patentable) and 71.7% of challenged claims were cancelled.

In comparison, in the 323 final written decisions in all IPRs 82.5% of instituted claims have been cancelled and 75.3% of challenged claims have been cancelled.

In the same session, Sterne Kessler’s Eric Steffe gave an overview of PTAB cases that have been appealed to the Federal Circuit. He said 141 appeals from final IPR/CBM decisions were docketed at the Federal Circuit. Of these, 104 (75%) are by patent owners, 18 (13%) are by petitioners and 19 (12%) are cross appeals by both parties,

Nine percent of the appeals are from the biotech/chemistry area, with 13 appeals. Nine of these are by patent owners and four are by petitioners, which Steffe said is “roughly mirroring other technologies in terms of who is making those appeals”.



more from across site and ros bottom lb

More from across our site

We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The FTC’s plans to scrutinise improperly listed Orange Book patents could make these listings more important in litigation, but firms should be looking at this anyway
Counsel at Debevoise & Plimpton explain how they helped food delivery business Grubhub avoid a preliminary injunction at the Court of Appeals for the Seventh Circuit
European lawyers tell Managing IP how the legal market is reacting to the first few months of the UPC and why cases are set to take off
The ban could be extended or cancelled, depending on whether Judge Pauline Newman cooperates with an investigation, the Judicial Council of the Federal Circuit stated
Sources say some China-based lawyers are prepared to take large pay cuts to join stable practices, but most firms are sceptical about new hires
Lord Justice Colin Birss used ChatGPT to help him write a judgment, a development that has generated plenty of debate but which is perhaps inevitable
The decision marks the first time the Unified Patent Court has issued a preliminary injunction after an oral hearing involving both sides in a dispute
The German carmaker is the second licensee to sign up to Avanci’s 5G pool following its launch last month
Managing IP presents the third edition of its Ones to Watch list, profiling 22 in-house counsel on the rise